Luye Pharma Group has announced submission of a new drug application (NDA) to the U.S. Food and Drug Administration (“FDA”) for Rykindo®, completed on March 28. Rykindo® (LY03004) Risperidone Extend...
Luye Pharma released its annual results on March 28. The financial report show that in 2018, the company realized revenue of 5.173 billion RMB, up 35.6% year-on-year; EBITDA reached 1.961 billion RMB,...
Vela announces FDA submission for the Sentosa® SQ HIV Genotyping Assay, a NGS genotyping and DRM detection IVD test intended for use as an aid in monitoring and treating HIV-1 infection.Vela Diagnosti...
Luye Pharma Group has announced that the company’s new drug candidate for the treatment of schizophrenia and schizoaffective disorders, Paliperidone Palmitate Injectable Suspension for Intramusc...
Luye Pharma has announced the acquisition of two investigational biological antibodies being developed by Shandong Boan Biological Technology Co., Ltd. Luye Pharma has a carefully formulated strategy ...
Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma’s Xuezhikang Capsules in mainland...
Luye Pharma Group has announced that its Central Nervous System (CNS) drug, Seroquel XR (Quetiapine Fumarate XR), has received approval from the official Chinese medical authorities for a new indicati...
Luye Pharma Group has announced that the company’s new compound candidate, extended release tablet ‘LY03012’, a China Class 1 new chemical drug, has been approved by the National Med...
On September 4, Luye Pharma announced that its independently developed drug, Goserelin Acetate Extended-release Microspheres for Injection (LY01005), has entered phase III clinical trials for prostate...
Luye Pharma Group has announced that import registration procedures for one of the company’s core central nervous system (CNS) products, ‘Rivastigmine Transdermal Patches’, have been...
TOP